Literature DB >> 1374678

Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer.

F C Hamdy1, J Lawry, J B Anderson, M A Parsons, R C Rees, J L Williams.   

Abstract

Analytical flow cytometry was used to study circulating prostate specific antigen (PSA)-positive cells in 40 consecutive patients with newly diagnosed, untreated prostate cancer; 25 patients (63%) had metastatic disease confirmed by a positive bone scan. Cell suspensions were prepared for each patient from both the primary tumour and peripheral blood samples. The cells were stained with a monoclonal antibody against PSA, and analysed by flow cytometry; PSA-positive cells were sorted according to their immunofluorescence and light scatter properties. The cellular deoxyribonucleic acid (DNA) content of each specimen was also analysed to establish ploidy status. PSA-positive cells were detected in the peripheral blood of 33 patients (83%). The presence of these cells in the circulation showed a higher degree of sensitivity and specificity in predicting positive bone scans than did serum PSA levels. Circulating PSA-positive cells may represent either a subpopulation of tumour cells with distinct metastatic properties or, alternatively, host immunocytes which take up PSA in an active or passive manner.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374678     DOI: 10.1111/j.1464-410x.1992.tb15566.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  6 in total

1.  [Prostate cancer screening with a new marker based on circulating blood macrophages?].

Authors:  R Herwig; B Djavan; G Kramer; M A El-Taieb; F Kühhas; M Leers; M Marberger
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 2.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

3.  Detection of circulating prostate-specific antigen-positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction.

Authors:  E J Fadlon; R C Rees; C McIntyre; R M Sharrard; J Lawry; F C Hamdy
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

4.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.

Authors:  H Uemura; Y Nakagawa; K Yoshida; S Saga; K Yoshikawa; Y Hirao; E Oosterwijk
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

5.  Prostate-specific membrane antigen-derived primers in a nested reverse transcription polymerase chain reaction for detecting prostatic cancer cells.

Authors:  A Saimoto; S Saito; M Murai
Journal:  Jpn J Cancer Res       Date:  1999-02

6.  Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer.

Authors:  Yi Lu; Yu Zhang; Guimin Chang; Jun Zhang
Journal:  Biomed Res Int       Date:  2013-01-31       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.